Glitazones raise risk of fractures

Glitazone treatment for type-2 diabetes increases the risk of osteoporotic fracture two to three-fold, according to data presented at the symposium.

The analysis of patient records included 1,020 type-2 diabetes patients, aged 50-89 years with a fracture, and 3,700 diabetic non-fracture controls.

It showed men and women taking glitazones had an increased risk of non-vertebral and hip fractures independent of BMI or other comorbidities. The rate of hip fracture was more than four times higher.

The study found no increased risk associated with metformin or sulphonylurea treatment.

Lead researcher Dr Christian Meier from University Hospital in Basel, said: 'We observed the same effect for both pioglitazone and rosiglitazone. It seems to represent a class effect.'

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus